Introduction
Vascular Cognitive Impairment (VCI) represents a significant and growing public health challenge, particularly among the elderly. It encompasses a spectrum of cognitive deficits resulting from cerebrovascular disease, ranging from mild impairment to full-blown vascular dementia. In China, the burden is particularly high, with millions affected. Despite its prevalence, the pharmaceutical landscape for VCI remains limited, often relying on Western medications like cholinesterase inhibitors and memantine, which provide only modest symptomatic relief.
Traditional Chinese Medicine (TCM) has been employed for thousands of years to treat symptoms associated with dementia. While contemporary studies suggest TCM can improve cognitive function and quality of life, there is a distinct lack of high-quality, large-scale evidence. Specifically, the relationship between TCM "syndromes" (ZHENG) and treatment efficacy, as well as the underlying biological mechanisms, remains poorly understood. The REVIEW-TCM study (REgistry for Vascular cognitive Impairment trEatment With Traditional Chinese Medicine) was designed to address these gaps by evaluating TCM in a real-world clinical setting.
Study Design and Participants
The REVIEW-TCM is a prospective, observational disease registry study. Unlike traditional randomized controlled trials (RCTs) that often have strict, narrow inclusion criteria, this registry aims to capture the diversity of real-world clinical practice. By observing how TCM is naturally integrated into patient care, researchers can gain insights into the effectiveness and safety of various herbal formulas and combination therapies.
The study aims to recruit 1,000 patients from the Hunan Hospital of Integrated Traditional Chinese and Western Medicine. The recruitment period spans from late 2022 through the end of 2027.
As shown in the recruitment protocol, participants must be at least 18 years old and meet specific diagnostic thresholds, including a Montreal Cognitive Assessment (MoCA) score below 26 and a Hachinski Ischemic Score (HIS) greater than 6. The exclusion criteria are comprehensive, ensuring that cognitive impairment is primarily vascular in origin rather than due to neurodegenerative diseases like Alzheimer's or Parkinson's.
Intervention and Methodology
A defining feature of the REVIEW-TCM study is its flexible approach to intervention. There are no strict limitations placed on the specific TCM treatments administered, reflecting the personalized nature of traditional practice.
Researchers will meticulously document the details of TCM prescriptions, including specific herbs, formulations (such as Chinese patent medicines or decoctions), treatment duration, and patient compliance. Concomitant Western treatments, such as donepezil or memantine, are permitted and will be recorded to analyze potential synergistic effects.
The study employs a mixed-methods embedded design. This approach combines quantitative data—such as clinical rating scales and biological markers—with qualitative data derived from in-depth interviews with patients and their caregivers. This dual focus allows the study to capture patient-reported outcomes (PROs) that traditional cognitive tests might overlook, such as changes in emotional well-being or the perceived burden on the family.
Data Collection and Outcomes
Data is managed through a centralized electronic data capture (EDC) system to ensure accuracy and completeness. The primary outcome measure is the change in MoCA scores from baseline to 12 and 24 months. Secondary outcomes include:
- Cognitive Domains: Executive function (Trail Making Tests) and language (Boston Naming Test).
- Daily Functioning: Instrumental Activities of Daily Living (IADL).
- Biological Markers: Neuroimaging (Diffusion Tensor Imaging) to assess white matter integrity and biomarkers like Neurofilament Light Chain (NFL) and Vascular Endothelial Growth Factor (VEGF).
- Caregiver Impact: The Zarit Burden Interview (ZBI) will assess the stress levels of those caring for VCI patients.
To address the inherent biases of an observational study, the researchers will utilize Propensity Score Matching (PSM). This statistical method will help create comparable groups of patients receiving TCM versus those receiving standard Western care, allowing for a more robust analysis of treatment effectiveness.
Discussion and Future Directions
The REVIEW-TCM study represents a significant step toward "precision TCM" for vascular cognitive impairment. By integrating advanced neuroimaging and biomarkers with traditional syndrome differentiation (ZHENG), the study aims to identify which patient subtypes respond best to specific herbal interventions.
While the single-center design and the observational nature of the registry present certain limitations regarding generalizability and bias, the large sample size and rigorous statistical plan provide a strong foundation for future findings. Ultimately, this registry will provide the real-world evidence needed to guide clinicians in choosing the most effective and safe TCM therapies for the diverse population of patients living with VCI.
Summary updated